These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

225 related articles for article (PubMed ID: 31306750)

  • 1. Bridging in vitro dissolution and in vivo exposure for acalabrutinib. Part II. A mechanistic PBPK model for IR formulation comparison, proton pump inhibitor drug interactions, and administration with acidic juices.
    Pepin XJH; Moir AJ; Mann JC; Sanderson NJ; Barker R; Meehan E; Plumb AP; Bailey GR; Murphy DS; Krejsa CM; Andrew MA; Ingallinera TG; Slatter JG
    Eur J Pharm Biopharm; 2019 Sep; 142():435-448. PubMed ID: 31306750
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Bridging in vitro dissolution and in vivo exposure for acalabrutinib. Part I. Mechanistic modelling of drug product dissolution to derive a P-PSD for PBPK model input.
    Pepin XJH; Sanderson NJ; Blanazs A; Grover S; Ingallinera TG; Mann JC
    Eur J Pharm Biopharm; 2019 Sep; 142():421-434. PubMed ID: 31306753
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Physiologically Based Absorption Modelling to Explore the Formulation and Gastric pH Changes on the Pharmacokinetics of Acalabrutinib.
    Zhou D; Chen B; Sharma S; Tang W; Pepin X
    Pharm Res; 2023 Feb; 40(2):375-386. PubMed ID: 35478298
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Physiologically Based Pharmacokinetic Modeling Approach to Identify the Drug-Drug Interaction Mechanism of Nifedipine and a Proton Pump Inhibitor, Omeprazole.
    Le Merdy M; Tan ML; Sun D; Ni Z; Lee SC; Babiskin A; Zhao L
    Eur J Drug Metab Pharmacokinet; 2021 Jan; 46(1):41-51. PubMed ID: 33064292
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Physiologically Based Biopharmaceutics Modeling for Gefapixant IR Formulation Development and Defining the Bioequivalence Dissolution Safe Space.
    Wang M; Heimbach T; Zhu W; Wu D; Reuter KG; Kesisoglou F
    AAPS J; 2024 Jun; 26(4):69. PubMed ID: 38862807
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Evaluation of the Drug-Drug Interaction Potential of Acalabrutinib and Its Active Metabolite, ACP-5862, Using a Physiologically-Based Pharmacokinetic Modeling Approach.
    Zhou D; Podoll T; Xu Y; Moorthy G; Vishwanathan K; Ware J; Slatter JG; Al-Huniti N
    CPT Pharmacometrics Syst Pharmacol; 2019 Jul; 8(7):489-499. PubMed ID: 31044521
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Development of a Physiologically Relevant Population Pharmacokinetic in Vitro-in Vivo Correlation Approach for Designing Extended-Release Oral Dosage Formulation.
    Kim TH; Shin S; Bulitta JB; Youn YS; Yoo SD; Shin BS
    Mol Pharm; 2017 Jan; 14(1):53-65. PubMed ID: 27809538
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Improving Dissolution Behavior and Oral Absorption of Drugs with pH-Dependent Solubility Using pH Modifiers: A Physiologically Realistic Mass Transport Analysis.
    Salehi N; Kuminek G; Al-Gousous J; Sperry DC; Greenwood DE; Waltz NM; Amidon GL; Ziff RM; Amidon GE
    Mol Pharm; 2021 Sep; 18(9):3326-3341. PubMed ID: 34428047
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Bioequivalence and Relative Bioavailability Studies to Assess a New Acalabrutinib Formulation That Enables Coadministration With Proton-Pump Inhibitors.
    Sharma S; Pepin X; Burri H; Zheng L; Kuptsova-Clarkson N; de Jong A; Yu T; MacArthur HL; Majewski M; Byrd JC; Furman RR; Ware JA; Mann J; Ramies D; Munugalavadla V; Sheridan L; Tomkinson H
    Clin Pharmacol Drug Dev; 2022 Nov; 11(11):1294-1307. PubMed ID: 36029150
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Acalabrutinib CYP3A-mediated drug-drug interactions: Clinical evaluations and physiologically based pharmacokinetic modelling to inform dose adjustment strategy.
    Chen B; Zhou D; Wei H; Yotvat M; Zhou L; Cheung J; Sarvaria N; Lai R; Sharma S; Vishwanathan K; Ware J
    Br J Clin Pharmacol; 2022 Aug; 88(8):3716-3729. PubMed ID: 35165925
    [TBL] [Abstract][Full Text] [Related]  

  • 11. In vitro dissolution methodology, mini-Gastrointestinal Simulator (mGIS), predicts better in vivo dissolution of a weak base drug, dasatinib.
    Tsume Y; Takeuchi S; Matsui K; Amidon GE; Amidon GL
    Eur J Pharm Sci; 2015 Aug; 76():203-12. PubMed ID: 25978875
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Bioavailability of acalabrutinib suspension delivered via nasogastric tube in the presence or absence of a proton pump inhibitor in healthy subjects.
    Sharma S; Pepin X; Cheung J; Zheng L; Wei H; Townsley D; Han D; Majewski M; Ware JA; Mann J; Munugalavadla V; Sheridan L; Patel P; Gupta A; Tomkinson H
    Br J Clin Pharmacol; 2022 Oct; 88(10):4573-4584. PubMed ID: 35466438
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Utilizing in vitro and PBPK tools to link ADME characteristics to plasma profiles: case example nifedipine immediate release formulation.
    Wagner C; Thelen K; Willmann S; Selen A; Dressman JB
    J Pharm Sci; 2013 Sep; 102(9):3205-19. PubMed ID: 23696038
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Simultaneous Ivabradine Parent-Metabolite PBPK/PD Modelling Using a Bayesian Estimation Method.
    Lang J; Vincent L; Chenel M; Ogungbenro K; Galetin A
    AAPS J; 2020 Oct; 22(6):129. PubMed ID: 33033962
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Prediction of ARA/PPI Drug-Drug Interactions at the Drug Discovery and Development Interface.
    Dodd S; Kollipara S; Sanchez-Felix M; Kim H; Meng Q; Beato S; Heimbach T
    J Pharm Sci; 2019 Jan; 108(1):87-101. PubMed ID: 30385285
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Interplay of metabolism and transport in determining oral drug absorption and gut wall metabolism: a simulation assessment using the "Advanced Dissolution, Absorption, Metabolism (ADAM)" model.
    Darwich AS; Neuhoff S; Jamei M; Rostami-Hodjegan A
    Curr Drug Metab; 2010 Nov; 11(9):716-29. PubMed ID: 21189140
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Improved characterization of the pharmacokinetics of acalabrutinib and its pharmacologically active metabolite, ACP-5862, in patients with B-cell malignancies and in healthy subjects using a population pharmacokinetic approach.
    Edlund H; Bellanti F; Liu H; Vishwanathan K; Tomkinson H; Ware J; Sharma S; Buil-Bruna N
    Br J Clin Pharmacol; 2022 Feb; 88(2):846-852. PubMed ID: 34265100
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Population Pharmacokinetics of the BTK Inhibitor Acalabrutinib and its Active Metabolite in Healthy Volunteers and Patients with B-Cell Malignancies.
    Edlund H; Lee SK; Andrew MA; Slatter JG; Aksenov S; Al-Huniti N
    Clin Pharmacokinet; 2019 May; 58(5):659-672. PubMed ID: 30556110
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Comparison of Deconvolution-Based and Absorption Modeling IVIVC for Extended Release Formulations of a BCS III Drug Development Candidate.
    Kesisoglou F; Xia B; Agrawal NG
    AAPS J; 2015 Nov; 17(6):1492-500. PubMed ID: 26290380
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Model-Based Analysis of Biopharmaceutic Experiments To Improve Mechanistic Oral Absorption Modeling: An Integrated in Vitro in Vivo Extrapolation Perspective Using Ketoconazole as a Model Drug.
    Pathak SM; Ruff A; Kostewicz ES; Patel N; Turner DB; Jamei M
    Mol Pharm; 2017 Dec; 14(12):4305-4320. PubMed ID: 28771009
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 12.